Biologic response modifiers presently approved in the USA for use in various rheumatic inflammatory diseases include three TNF inhibitors (etanercept, infliximab and adalimumab), a B-cell-directed ...
The potential of biologic agents to influence malignant processes has revolutionized cancer therapy. The biologic therapy causes modulation of immune responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback